Ionis Pharmaceuticals Inc  

(Public, NASDAQ:IONS)   Watch this stock  
Find more results for NASDAQ:ISIS
30.90
+0.53 (1.75%)
Aug 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 30.14 - 31.21
52 week 19.59 - 65.34
Open 30.23
Vol / Avg. 1.87M/2.93M
Mkt cap 3.59B
P/E     -
Div/yield     -
EPS -1.88
Shares 120.92M
Beta 2.13
Inst. own 91%
Nov 7, 2016
Q3 2016 Ionis Pharmaceuticals Inc Earnings Release (Estimated) Add to calendar
Sep 8, 2016
Ionis Pharmaceuticals Inc at Wells Fargo Securities Healthcare Conference - 2:20PM EDT - Add to calendar
Aug 9, 2016
Q2 2016 Ionis Pharmaceuticals Inc Earnings Call
Aug 9, 2016
Q2 2016 Ionis Pharmaceuticals Inc Earnings Release
Aug 1, 2016
Biogen Inc and Ionis Pharmaceuticals Inc Nusinersen ENDEAR Interim Webcast - Webcast
Jul 13, 2016
Ionis Pharmaceuticals Inc R&D Day - Webcast
Jun 8, 2016
Ionis Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference
Jun 3, 2016
Ionis Pharmaceuticals Inc Annual Shareholders Meeting
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin -147.79% -31.12%
Operating margin -127.18% -26.70%
EBITD margin - -23.10%
Return on average assets -27.04% -9.27%
Return on average equity -169.31% -38.50%
Employees 428 -
CDP Score - -

Address

2855 Gazelle Ct
CARLSBAD, CA 92010-6670
United States - Map
+1-760-9319200 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Ionis Pharmaceuticals, Inc., formerly Isis Pharmaceuticals, Inc., is engaged in discovering and developing ribonucleic acid-targeted (RNA-targeted) therapeutics. The Company operates through two segments: Ionis Core and Akcea Therapeutics. The Company's Ionis Core segment is developing a drug discovery platform. The Company's Akcea Therapeutics segment consists of the operations of its subsidiary, Akcea Therapeutics, Inc., which develops and commercializes drugs for cardiometabolic disorders. The Company is developing transformational drugs, which include nusinersen, IONIS-TTR and volanesorsen that are designed to treat patients with orphan diseases. In addition to its Phase III programs, the Company has a pipeline of drugs in Phase II development, which includes IONIS-FXI and IONIS-APO(a)-L. Its Phase II pipeline includes drugs to treat patients with severe and rare diseases, viral infections, ocular diseases, metabolic disorders and cardiovascular diseases.

Officers and directors

Stanley T. Crooke M.D., Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 70
Bio & Compensation  - Reuters
Elizabeth L. Hougen Chief Financial Officer, Senior Vice President - Finance
Age: 54
Bio & Compensation  - Reuters
B. Lynne Parshall J.D. Chief Operating Officer, Corporate Secretary, Director
Age: 61
Bio & Compensation  - Reuters
Patrick R. O'Neil Esq. Senior Vice President, Legal, General Counsel and Corporate Secretary
Age: 42
Bio & Compensation  - Reuters
C. Frank Frank Bennett Ph.D. Senior Vice President - Antisense Research
Age: 59
Bio & Compensation  - Reuters
Richard S. Geary Ph.D. Senior Vice President - Development
Age: 58
Bio & Compensation  - Reuters
Brett P. Monia Ph.D. Senior Vice President - Drug Discovery and Corporate Development
Age: 54
Bio & Compensation  - Reuters
Sarah Boyce Chief Business Officer
Age: 44
Bio & Compensation  - Reuters
Joseph Loscalzo M.D., Ph.D. Director
Age: 63
Bio & Compensation  - Reuters
Spencer R. Berthelsen M.D. Independent Director
Age: 63
Bio & Compensation  - Reuters